Investor Presentaiton

ESTELLE® in the US: NEXTSTELLISⓇ highlights 35.000 30.000 25.000 20.000 15.000 10.000 5.000 0 NEXSTELLISⓇ monthly performance metrics from 2Q-2022 to 2Q-2023 mars-23 avr-22 mai-22 juin-22 juil-22 août-22 sept-22 oct-22 nov-22 déc-22 janv-23 févr-23 Total Cycles avr-23 mai-23 juin-23 -Cycles NRx RRx 350.000 • 300.000 250.000 200.000 150.000 100.000 50.000 • 0 TRX NEXTSTELLISⓇ growth is accelerating thanks to new commercial strategy implemented by Mayne in December 2022 NEXTSTELLISⓇ has continued to achieve solid growth during 1H-2023 to date driven by access improvements (Co-Pay) and new targeting strategy implemented by Mayne in December 2022 • > 314,000 cycles dispensed since launch in June 2021 > 161,000 cycles dispensed in 6 months since January 2023 > 7,500 weekly cycles from now • Growth 2Q-2023 vs 1Q-2023 of NRx +19% and TRX +19% RRx expected to improve following patient retargeting initiative in December 2022 Experienced WH sales team of 94 (up from 86) able to reach target customers Net selling price returning to normal levels Direct-to-Consumer campaign launched in July 2022 with GoodRx and TV campaign launched in February 2023 with other marketing avenues being explored Mithra Investor Presentation - November 2023 21

View entire presentation